[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20034323D0 - Medisinske aerosolformuleringer - Google Patents

Medisinske aerosolformuleringer

Info

Publication number
NO20034323D0
NO20034323D0 NO20034323A NO20034323A NO20034323D0 NO 20034323 D0 NO20034323 D0 NO 20034323D0 NO 20034323 A NO20034323 A NO 20034323A NO 20034323 A NO20034323 A NO 20034323A NO 20034323 D0 NO20034323 D0 NO 20034323D0
Authority
NO
Norway
Prior art keywords
aerosol formulations
salts
medical aerosol
medical
dosing
Prior art date
Application number
NO20034323A
Other languages
English (en)
Other versions
NO332848B1 (no
NO20034323L (no
Inventor
Rudi Mueller-Walz
Carsten Niederlaender
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of NO20034323D0 publication Critical patent/NO20034323D0/no
Publication of NO20034323L publication Critical patent/NO20034323L/no
Publication of NO332848B1 publication Critical patent/NO332848B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20034323A 2001-03-30 2003-09-26 Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer. NO332848B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH6012001 2001-03-30
CH15272001 2001-08-20
PCT/CH2002/000145 WO2002078671A1 (de) 2001-03-30 2002-03-11 Medizinische aerosolformulierungen

Publications (3)

Publication Number Publication Date
NO20034323D0 true NO20034323D0 (no) 2003-09-26
NO20034323L NO20034323L (no) 2003-09-26
NO332848B1 NO332848B1 (no) 2013-01-21

Family

ID=25737693

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034323A NO332848B1 (no) 2001-03-30 2003-09-26 Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer.

Country Status (22)

Country Link
US (1) US20040101483A1 (no)
EP (1) EP1372608B1 (no)
JP (1) JP4824267B2 (no)
CN (1) CN100496608C (no)
AT (1) ATE375142T1 (no)
AU (1) AU2002234476B2 (no)
CA (1) CA2442415C (no)
CY (1) CY1107128T1 (no)
CZ (1) CZ301676B6 (no)
DE (1) DE50211045D1 (no)
DK (1) DK1372608T3 (no)
ES (1) ES2292713T3 (no)
HU (1) HU229798B1 (no)
NO (1) NO332848B1 (no)
NZ (1) NZ528640A (no)
PL (1) PL207377B1 (no)
PT (1) PT1372608E (no)
RO (1) RO121172B1 (no)
RU (1) RU2294737C2 (no)
SK (1) SK286394B6 (no)
WO (1) WO2002078671A1 (no)
ZA (1) ZA200307161B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
JP2005507881A (ja) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
PL212725B1 (pl) * 2002-12-10 2012-11-30 Sepracor Inc L-winian lewalbuterolu w postaci krystalicznej oraz kompozycja farmaceutyczna zawierajaca L-winian lewalbuterolu
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
SI1713473T1 (sl) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
EP1718336B1 (en) 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
NZ548301A (en) 2004-02-06 2010-07-30 Meda Pharma Gmbh & Co Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
NZ560206A (en) 2005-03-16 2009-09-25 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
AU2006315657B2 (en) * 2005-11-10 2011-12-01 Shell Internationale Research Maatschappij B.V. Soft anticholinergic esters
PL1971369T3 (pl) 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
AU2015201864A1 (en) * 2009-05-29 2015-04-30 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
AR076806A1 (es) * 2009-05-29 2011-07-06 Pearl Therapeutics Inc Composiciones para el suministro de agentes activos mediante las vias res-piratorias, y metodos y sistemas asociados, cosuspension, inhalador dosifi-cador
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
RU2567040C2 (ru) * 2009-12-23 2015-10-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
KR101757951B1 (ko) 2009-12-23 2017-07-13 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 조합요법
HRP20140550T1 (hr) 2009-12-23 2014-07-18 Chiesi Farmaceutici S.P.A. Aerosolna formulacija za copd
JP5513177B2 (ja) * 2010-03-08 2014-06-04 共同印刷株式会社 湿度インジケータとその製造方法、該製造方法に用いる湿度インジケータ用塗料
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
PL2765994T3 (pl) * 2011-10-11 2019-09-30 Chiesi Farmaceutici S.P.A. Krystaliczne mikrocząstki beta-agonisty pokryte kwasem tłuszczowym
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
US20190099344A1 (en) * 2016-04-11 2019-04-04 Suven Life Sciences Limited Topical spray formulation of glycopyrrolate

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1096357A (en) * 1965-02-11 1967-12-29 Fisons Pharmaceuticals Ltd Aerosol compositions
JPS55361B1 (no) * 1970-09-17 1980-01-08
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH06135815A (ja) * 1992-10-30 1994-05-17 Shiseido Co Ltd 経皮吸収抑制組成物
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE4321288A1 (de) * 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
CA2176249C (en) * 1993-12-02 2010-06-01 Akwete L. Adjei Aerosol drug formulations for use with non-cfc propellants
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP3707107B2 (ja) * 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6261472B1 (en) * 1996-11-04 2001-07-17 E. I. Du Pont De Nemours And Company Azeotrope-like compositions containing fluoroethane
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
CA2279648C (en) * 1997-01-30 2007-04-24 Alpenstock Holdings Limited Haemostatic aerosol composition
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CA2338753C (en) * 1998-07-24 2006-11-21 Jago Research Ag Medicinal aerosol formulations
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EA005179B1 (ru) * 2000-05-22 2004-12-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические препараты в виде растворов для дозированных ингаляторов под давлением
EP1311294A2 (en) * 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
ES2296831T3 (es) * 2000-11-30 2008-05-01 Vectura Limited Metodo para preparar microparticulas para usar en composiciones farmaceuticas para inhalacion.
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
WO2003074024A1 (en) * 2002-03-01 2003-09-12 Chiesi Farmaceutici S.P.A Formoterol superfine formulation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation

Also Published As

Publication number Publication date
CA2442415C (en) 2010-07-20
DK1372608T3 (da) 2007-12-27
CN100496608C (zh) 2009-06-10
PL362797A1 (en) 2004-11-02
CN1499958A (zh) 2004-05-26
PT1372608E (pt) 2008-01-04
SK286394B6 (sk) 2008-09-05
CZ20032915A3 (en) 2004-06-16
PL207377B1 (pl) 2010-12-31
NO332848B1 (no) 2013-01-21
CY1107128T1 (el) 2012-10-24
EP1372608A1 (de) 2004-01-02
WO2002078671A1 (de) 2002-10-10
HK1064295A1 (zh) 2005-01-28
ES2292713T3 (es) 2008-03-16
SK13342003A3 (sk) 2004-08-03
HU229798B1 (en) 2014-07-28
CZ301676B6 (cs) 2010-05-19
HUP0401250A2 (hu) 2004-11-29
ATE375142T1 (de) 2007-10-15
RU2294737C2 (ru) 2007-03-10
JP2004525148A (ja) 2004-08-19
EP1372608B1 (de) 2007-10-10
AU2002234476B2 (en) 2006-04-27
JP4824267B2 (ja) 2011-11-30
NZ528640A (en) 2004-06-25
ZA200307161B (en) 2005-01-26
US20040101483A1 (en) 2004-05-27
RU2003131676A (ru) 2005-02-10
AU2002234476C1 (en) 2002-10-15
NO20034323L (no) 2003-09-26
CA2442415A1 (en) 2002-10-10
RO121172B1 (ro) 2007-01-30
HUP0401250A3 (en) 2008-04-28
DE50211045D1 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
DK1372608T3 (da) Medicinske aerosolformuleringer
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
DK1102579T3 (da) Medicinske aerosolformuleringer
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
HUP0400520A2 (hu) Klindamicint és cinksót tartalmazó dermatológiai készítmények
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
UY27373A1 (es) Formulaciones de interferón beta-humano
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
DE60033416D1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use
BRPI0410021A (pt) preparação farmacêutica sólida, que contém sais levotiroxina e/ou liotironina como substáncia ativa

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees